Orexigen Files for IPO

Orexigen Therapeutics Inc., a San Diego-based drug company focused on central nervous systems disorders, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol OREX, with Merrill Lynch and JPMorgan serving as co-lead underwriters. Orexigen has raised around $76 million in total VC funding since its 2003 inception, from firms like Domain Associates, Kleiner Perkins Caufield & Byers, BA Venture Partners, MPM Capital, Duke University, Montreux Equity Partners, Morgenthaler Ventures, Sofinnova Ventures and Wasatch Venture Fund. www.orexigen.com